Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
    • CFP AI policy
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
    • CFP AI policy
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticleResearch

Are we ready for human papillomavirus testing?

Assessment of patient knowledge of and preferences for cervical cancer screening in Ontario

Praniya Elangainesan, Michelle S. Naimer, Sahana Kukan and Amanda Selk
Canadian Family Physician July/August 2024; 70 (7-8) 479-490; DOI: https://doi.org/10.46747/cfp.700708479
Praniya Elangainesan
Medical student at the University of Toronto in Ontario.
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle S. Naimer
Family physician at Mount Sinai Hospital in Toronto and Associate Professor in the Department of Family and Community Medicine at the University of Toronto.
MD CCFP MHSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sahana Kukan
Research assistant in the Department of Family Medicine at Mount Sinai Hospital.
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Selk
Obstetrician gynecologist at Mount Sinai Hospital and Associate Professor in the Department of Obstetrics and Gynaecology at the University of Toronto.
MD MSc FRCSC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: amanda.selk{at}utoronto.ca
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Objective To determine patient knowledge and preferences about primary human papillomavirus (HPV) testing.

Design Cross-sectional survey.

Setting Two family practice clinics (urban and suburban) and the social media platforms of 2 hospitals in the greater Toronto area between January and February 2023.

Participants A total of 413 Ontario residents aged 25 to 69 years, with a cervix, who qualified for Papanicolaou (Pap) screening and could communicate in English.

Methods Electronic survey containing questions about knowledge of, and preferences for, cervical cancer screening, including types of screening and screening intervals, and about education related to HPV and screening intervals.

Main findings Of 441 potential participants, 426 were eligible and consented to participate in the study; ultimately 413 provided completed or partially completed surveys (96.9% response rate). Of those who completed a recent Pap test, 57.8% (208 of 360) knew of HPV testing. Initially, 27.8% thought HPV testing was better than Pap testing for cervical cancer screening. After learning HPV tests exist and have self-sampling options, most participants preferred HPV testing (self-sampling 46.3%, provider sampling 34.1%). Annual cervical cancer screening was preferred by 50.1% of participants despite knowing that, for most people, Pap tests should be conducted every 3 years (74.8%). After learning about HPV testing, participants were more likely to prefer 5-year screening intervals (43.8%); however, those in the family practice group were still more likely to prefer 3-year intervals compared with those in the social media group (P<.01).

Conclusion Participants in this study identified a preference for HPV testing and self-sampling options. Concerns were raised about extended screening intervals and the safety of self-collected samples that need to be addressed in public health education initiatives during rollout of new screening programs.

Cervical cancer is the fourth most common cancer in women worldwide.1 Almost all (99.7%) cases are linked to high-risk human papillomavirus (HPV) infection.2 Prince Edward Island is the only Canadian province where HPV testing is used for primary cervical cancer screening; however, 6 other provinces and 1 territory had plans to implement it as of 2022.3 Currently, cervical cancer screening relies on cervical cytology (Papanicolaou [Pap] tests). However, primary HPV testing has been found to better detect precancers and cancers than Pap tests.4-6 A 2018 landmark trial found HPV testing identified more lesions otherwise missed by cytology.7 Consequently, Ontario Health (Cancer Care Ontario)8 intends to replace Pap tests with HPV tests over 5 years, beginning in 2025. Screening intervals will also change to 5 years, from 3 years, for those at average risk of cervical cancer who receive a negative HPV test result.9,10 In addition, the Canadian Task Force on Preventive Health Care recommends screening initiation at age 25 years instead of 21 years.11 Australia and the Netherlands have already successfully implemented primary HPV screening into national programs.12,13

Prior to large-scale screening program changes, effective public education and rollout strategies are crucial. In Australia, implementation faced opposition due to mistrust and concerns about the extended screening interval as a cost-saving measure.12,14 Acceptance from providers and patients is essential to maintaining screening rates. Ontario is planning HPV screening with provider-collected vaginal samples, while other regions will allow self-vaginal sampling. Pilot projects are under way to assess urine HPV screening in Halifax, NS.15

As primary HPV screening is introduced across Canada, understanding public knowledge and preferences is important for the development of effective public education and rollout strategies. The primary objective of this study was to determine current knowledge of, and preferences for, primary HPV testing among Ontario residents, aged 25 to 69 years, with a cervix, to aid in developing public education materials for the transition to HPV testing.

METHODS

Study design

A cross-sectional study was designed to assess patient knowledge of, and preferences for, primary HPV testing. Research Ethics Board approval was obtained from Mount Sinai Hospital (REB 22-0111-E). Data were collected through an online survey based on a modified version used in an Alberta family practice HPV preference study.16 The survey collected participant demographic characteristics; Pap screening history; experiences with Pap screening; knowledge of HPV testing; knowledge of accuracy, safety, and benefits of HPV testing compared with Pap screening; and preference of screening intervals or type of screening (eg, no screening, Pap test, provider-collected HPV, patient-collected HPV, urine-based HPV). The 2 sample populations included in the survey were the general public and family practice patients. Based on a 95% confidence interval and aiming to achieve a margin of error of less than 5%, the calculated required sample size was 384 participants.

Participants were asked whether their Pap screenings were current. If yes, participants were prompted to answer a question about awareness of HPV DNA testing. If no, participants were asked about reasons for having forgone Pap testing. The remaining questions were the same for all participants. After questions about preferences related to testing and screening intervals, participants were provided information about HPV testing and screening interval safety. Two additional questions were then asked to re-evaluate testing and screening preferences after participants had received this information.

Study population

The survey was posted on social media platforms (Twitter, Instagram, and Facebook) used by Sinai Health, a hospital system in Toronto, Ont, composed of 2 hospitals (Mount Sinai Hospital and Hennick Bridgepoint Hospital), and distributed to an academic family health team (a type of interdisciplinary primary health care practice in Ontario) with 2 sites: 1 in downtown Toronto and 1 in a suburban area of Vaughan, Ont. Participants were also recruited from the Mount Sinai Academic Family Health Team through an e-bulletin. Additionally, clinical patients were introduced to the study by doctors or nurse practitioners and provided with the survey link via a QR code located in an examination room or provided with a paper version of the survey to be completed and returned to a research assistant. As of July 2023 Sinai Health had 30,300 Twitter, 8562 Instagram, and 7700 Facebook followers, respectively. Survey data were collected between January and February 2023. Ontario residents aged 25 to 69 years, with a cervix, who qualified for Pap screening were eligible to participate. The survey was available in English only. Participants who could not read, write, or communicate in English were excluded.

Data analysis

Main outcome measures of the study included the percentage of participants who were up to date on cervical screening and aware of HPV testing; current attitudes toward extending screening intervals; and preferences for screening. Analyses were conducted using SAS version 9.4. Descriptive statistics were used to report survey data. Chi-square tests and Fisher exact test, where applicable, were used to assess categorical relationships between study groups. The threshold of statistical significance was P<.05.

RESULTS

A total of 441 people were initially recruited either in person at the family practice or online through social media. The e-bulletin was sent to 8761 email addresses and had an open rate of 75.6%. Overall, 426 participants were eligible for the study and consented to participate, and 413 participants completed or partially completed the survey, resulting in a response rate of 96.9% (Figure 1). Of 413 participants who completed the survey, 179 were recruited via social media while 234 were recruited in person or via the clinic e-bulletin (Table 1).

Figure 1.
  • Download figure
  • Open in new tab
Figure 1.

Participant inclusion and exclusion flowchart

View this table:
  • View inline
  • View popup
Table 1.

Participant characteristics, N=413

Sociodemographic characteristics

The mean (SD) age of social media participants was 41.9 (10.4) years, which was younger than family practice participants with a mean age of 46.6 (12.2) years (P<.01). Most participants had postsecondary education or higher (96.9%); lived in a location with more than 1,000,000 inhabitants (70.5%); had been born in Canada (78.0%); and had a family doctor (96.4%). Of those born outside Canada, 33.7% had moved to Canada before 10 years of age.

Experiences and knowledge of Pap testing

A total of 279 study participants (67.6%) knew most cervical cancer is caused by HPV (Table 2). Most participants (97.8%) had had a Pap test completed by a health professional. Female physicians had completed tests for 331 participants (81.9%). A total of 245 participants (60.6%) indicated Pap testing was not at all or minimally painful, while 100 (24.8%) found the test moderately or extremely painful. A total of 81 participants (20.0%) stated Pap tests were moderately or extremely embarrassing. Most participants (311; 77.0%) found that Pap tests were not at all or minimally time consuming.

View this table:
  • View inline
  • View popup
Table 2.

Participant experiences with Pap and HPV screening tests

Of the 404 participants who had had a previous Pap test, 360 (89.1%) had experienced the test during the previous 3 years. Of the 360 who had experienced a Pap test in the previous 3 years, 208 (57.8%) were aware of HPV testing for cervical cancer screening. More participants from the social media group were aware of HPV testing for cervical cancer screening compared with the family practice group (P=.02).

Among those who had not had a Pap test in the previous 3 years (n=35), the most frequently stated primary reason for forgoing testing was difficulty finding time for a Pap test (22.9%). Other reasons for forgoing testing included not knowing if or when a Pap test was required (17.1%), testing not suggested by a doctor (14.3%), Pap tests being uncomfortable or embarrassing (11.4%), not being sexually active (12.5%), hard to get an appointment (11.4%), and reminder for testing not provided (11.4%) (Table 2).

Of the 35 participants who had not had a Pap test in the previous 3 years, 13 (37.1%) were aware of HPV testing. While many (88.6%) were initially unaware of self-sampling, after being provided this information most (94.3%) felt self-sampling should be an option (Table 3). In the underscreened group, 24 participants (68.6%) preferred the option of HPV self-sampling.

View this table:
  • View inline
  • View popup
Table 3.

Participant knowledge regarding HPV testing options for those who have not had a Pap test in the past 3 years

Knowledge and preferences for HPV testing

At baseline, 291 participants (70.5%) felt HPV testing would not be better than Pap testing or were unsure (Table 4). More participants in the social media group (62 of 179) compared with the family practice group (53 of 234) (P=.03) believed HPV testing to be better than Pap testing. Most participants (83.1%) were unaware of self-sampling for cervical cancer screening. Similarly, a higher proportion of participants in the social media group (15.6%) were aware of self-sampling compared with the family practice group (8.5%) (P=.03). Most participants (89.1%) moderately or strongly agreed that people with a cervix should be given the option of HPV self-sampling. This sentiment was higher in the underscreened group at 94.3%.

View this table:
  • View inline
  • View popup
Table 4.

Participant knowledge regarding HPV testing options

A higher proportion of participants in the social media group compared with the family practice group (82.1% vs 69.2%; P<.01) were aware Pap tests should occur every 3 years. Participants in the family practice group were more likely to prefer annual cervical cancer screening (56.8%). The social media group preferred screening every 3 years (44.1%).

After participants received information stating that HPV testing is more accurate than Pap testing and that it can safely be done every 5 years, 80.4% preferred HPV testing, with 46.2% preferring to take their own HPV samples, compared with 34.1% who preferred to have them collected by a provider. Of the 35 participants who had not experienced a Pap test in the previous 3 years, 88.6% preferred HPV testing for future screening, with 68.6% also preferring the option to self-sample. Only 20% preferred to have a provider collect the sample.

After providing participants with information on the accuracy of HPV testing, the safety of 5-year screening intervals, and risks of over testing, 43.8% of participants (181 of 413) overall preferred 5-year screening over other screening intervals. However, there was a statistically significant difference between the 2 groups; social media participants preferred 5-year testing, while family practice participants preferred 3-year testing (P<.01). When informed about HPV testing using urine samples, 57.4% of all participants preferred this option.

DISCUSSION

This study aimed to understand the current knowledge of, and preferences for, HPV testing for cervical cancer in Ontario among participants recruited from social media and from urban and suburban family practice settings. Overall, most participants lacked awareness that HPV causes most cases of cervical cancer and that HPV testing is available as a screening option. There was uncertainty regarding the superiority of HPV testing compared with Pap testing. There was also little awareness of HPV self-sampling for cervical cancer as a screening option. Findings are consistent with current literature demonstrating little is known about HPV testing and self-screening options and that, once informed, many people prefer HPV self-screening if the option is available.17-19

Social media participants showed greater knowledge about HPV testing than family practice participants. This difference may be attributed to self-selection bias in the social media group, as individuals motivated and informed about HPV testing may have been more likely to participate in the survey. While it cannot be confirmed, it is also possible social media posts were more likely to appear in social media feeds of those interested in this topic.

Most participants in this study preferred self-sampling for cervical cancer screening. This was higher in the underscreened group, in keeping with a recent systematic review that found acceptability of self-sampling due to ease of collection, reduced embarrassment, comfort, and lack of pain.20 Lesack and colleagues found those more accepting of HPV-based screening over Pap testing were more willing to complete subsequent self-collection.17

Participants in this study indicated they would also prefer to provide urine samples, if given the option. Literature shows urine sampling is preferred due to convenience and ability to collect samples at home.21-23 A meta-analysis examining accuracy of cervical HPV detection in first-void urine reported a pooled sensitivity of 78% and specificity of 89% for high-risk HPV detection, compared with pooled sensitivity of 90% and specificity of 90% for cervical specimens.24 If improvements are made, and if urine testing for HPV were to become more comparable to other screening methods, considering urine sampling as an option would be important for improving participation rates.25

Prior to learning about cancer screening recommendations, participants preferred annual HPV cervical cancer screening, despite 74.8% being aware of the current 3-year Pap test interval. However, after receiving information about risks and benefits of HPV testing every 5 years, participants were more likely to prefer a 5-year interval. This interval had been found to be adequate, as long-term risk of high-grade preinvasive disease and cancers is low following a negative HPV DNA test.10 Nonetheless, 35.6% of participants still preferred 3-year intervals, indicating discomfort with extended screening intervals. Similarly, Smith et al found only 54% of their cohort was accepting of an extended screening interval, despite receiving education on this topic.26 While there are advantages to an extended screening interval, it will be important to implement strategies to reduce unintended consequences, such as reductions in chlamydia testing, and missed treatment opportunities. This occurred in Ontario in 2012 when cervical cancer screening guidelines changed to less frequent screening and older age of onset.27

This study identified potential mistrust regarding accuracy of self-sampling compared with provider-collected sampling. This is not uncommon and has been seen in both patients and providers.25,28 Several studies found similar accuracy between physician-obtained and patient-obtained samples for HPV testing.29,30 It is important to highlight benefits of self-sampling, as it can improve screening rates in underscreened communities lacking access to family doctors, in those with difficulty scheduling appointments, among patients with concerns about embarrassment or pain, and for those experiencing cultural barriers.22,31 Some patients will prefer provider sampling or require provider sampling due to mobility issues. These are important considerations when designing a screening program.

Limitations

Participants in this study were not reflective of the general Ontario population, as participants were highly educated individuals living in larger cities, most had family doctors, and most were up to date on Pap testing. The underscreened population is known to have lower knowledge of cervical cancer, HPV, and HPV testing,19 so this study demonstrates even in highly educated and screened populations, there are still knowledge gaps that need to be addressed when rolling out changes to screening programs. Another limitation of this study design was potential selection bias of participants by health care providers. Providers were given a written prompt to introduce the study to patients; however, patients were invited to participate in the study at the discretion of individual providers. Patients deemed to be good candidates may have been informed about the study. Those who received the family practice e-bulletin and hospital social media survey invitations had access to mobile devices or computers. Finally, the specific response rate is unknown, given the social media channels used for recruitment. Participants recruited through social media were compared with those with family practitioners to determine whether patients potentially without family physicians may have different readiness for HPV testing. This question could not be answered, as most people recruited through social media also had family physicians, and this group was similar to the recruited family practice group.

Conclusion

This study found a sample of Ontario residents preferred HPV testing and self-sampling over Pap tests. Preference was stronger among those without current screening. There are misconceptions and potential unintended consequences related to increased screening intervals and self-sampling. Educational campaigns should address these misconceptions and anticipate potential consequences to ensure successful transition to the new model and prevent drop-offs in screening rates.

Footnotes

  • Contributors

    All authors of this paper have directly participated in the planning, execution, or analysis of the study; all have read and approved the final submitted version.

  • Competing interests

    None declared

  • This article has been peer reviewed.

  • Cet article a fait l’objet d’une révision par des pairs.

  • Copyright © 2024 the College of Family Physicians of Canada

References

  1. 1.↵
    Cervical cancer elimination initiative. Geneva, Switz: World Health Organization; 2024. Available from: https://www.who.int/initiatives/cervical-cancer-elimination-initiative. Accessed 2023 Jun 23.
  2. 2.↵
    1. Okunade KS.
    Human papillomavirus and cervical cancer. J Obstet Gynaecol 2020;40(5):602-8. Epub 2019 Sep 10. Erratum in: J Obstet Gynaecol 2020;40(4):590. Epub 2020 Jan 31.
    OpenUrlPubMed
  3. 3.↵
    Cervical cancer screening in Canada: 2021/2022. Modalities for cervical screening. Toronto, ON: Canadian Partnership Against Cancer; 2022. Available from: https://www.partnershipagainstcancer.ca/topics/cervical-cancer-screening-in-canada-2021-2022/modalities-for-cervical-screening/hpv-testing. Accessed 2023 Jun 23.
  4. 4.↵
    1. Walboomers JM,
    2. Jacobs MV,
    3. Manos MM,
    4. Bosch FX,
    5. Kummer JA,
    6. Shah KV, et al.
    Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-9.
    OpenUrlCrossRefPubMed
  5. 5.
    The American Cancer Society guidelines for the prevention and early detection of cervical cancer. Atlanta, GA: American Cancer Society; 2021. Available from: https://www.cancer.org/cancer/types/cervical-cancer/detection-diagnosis-staging/cervical-cancer-screening-guidelines.html. Accessed 2023 May 05
  6. 6.↵
    1. Melnikow J,
    2. Henderson JT,
    3. Burda BU,
    4. Senger CA,
    5. Durbin S,
    6. Weyrich MS.
    Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2018;320(7):687-705.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Ogilvie GS,
    2. van Niekerk D,
    3. Krajden M,
    4. Smith LW,
    5. Cook D,
    6. Gondara L, et al.
    Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA 2018;320(1):43-52. Erratum in: JAMA 2018;320(21):2273.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Ontario Cervical Screening Program (OCSP): screening recommendations summary. Toronto, ON: Cancer Care Ontario; 2022. Available from: https://www.cancercareontario.ca/en/system/files_force/derivative/OCSPScreeningGuidelines.pdf. Accessed 2023 May 5.
  9. 9.↵
    1. Chao YS,
    2. McCormack S.
    HPV self-sampling for primary cervical cancer screening: a review of diagnostic test accuracy and clinical evidence—an update. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545378/pdf/Bookshelf_NBK545378.pdf. Accessed 2024 Jun 27.
  10. 10.↵
    1. Strang THR,
    2. Gottschlich A,
    3. Cook DA,
    4. Smith LW,
    5. Gondara L,
    6. Franco EL, et al.
    Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result. Am J Obstet Gynecol 2021;225(5):511.e1-7. Epub 2021 Jun 01.
    OpenUrl
  11. 11.↵
    Cervical cancer—clinician summary. Ottawa, ON: Canadian Task Force on Preventive Health Care; 2013. Available from: https://canadiantaskforce.ca/cervical-cancer-clinician-summary. Accessed 2023 May 5.
  12. 12.↵
    1. Dodd RH,
    2. Mac OA,
    3. McCaffery KJ.
    Women’s experiences of the renewed National Cervical Screening Program in Australia 12 months following implementation: a qualitative study. BMJ Open 2020;10(7):e039041.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Qendri V,
    2. Schurink-Van’t Klooster TM,
    3. Bogaards JA,
    4. Berkhof J.
    Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPV-related disease prevention. Expert Rev Vaccines 2018;17(12):1093-104. Epub 2018 Nov 29.
    OpenUrl
  14. 14.↵
    1. Obermair HM,
    2. Dodd RH,
    3. Bonner C,
    4. Jansen J,
    5. McCaffery K.
    ‘It has saved thousands of lives, so why change it?’ Content analysis of objections to cervical screening programme changes in Australia. BMJ Open 2018;8(2):e019171.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Cervical cancer screening in Canada: environmental scan. Toronto, ON: Canadian Partnership Against Cancer; 2018. Available from: https://www.partnershipagainstcancer.ca/wp-content/uploads/2019/01/Cervical-Cancer-Screening-Scan-EN-2018.pdf. Accessed 2023 Jun 4.
  16. 16.↵
    1. Kraut RY,
    2. Manca D,
    3. Lofters A,
    4. Hoffart K,
    5. Khan U,
    6. Liu S, et al.
    Attitudes toward human papillomavirus self-sampling in regularly screened women in Edmonton, Canada: a cross-sectional study. J Low Genit Tract Dis 2021;25(3):199-204.
    OpenUrl
  17. 17.↵
    1. Lesack A,
    2. Smith LW,
    3. Racey CS,
    4. Gondara L,
    5. Krajden M,
    6. Lee M, et al.
    Willingness to self-collect a sample for HPV-based cervical cancer screening in a well-screened cohort: HPV FOCAL survey results. Curr Oncol 2022;29(6):3860-9.
    OpenUrl
  18. 18.
    1. Ogden SN,
    2. Glanz K,
    3. Schapira MM,
    4. Bocage C,
    5. Eriksen W,
    6. Rendle KA.
    Patient perspectives on primary HPV testing for routine cervical cancer screening. J Gen Intern Med 2020;35(3):956-8. Epub 2019 Jul 16.
    OpenUrl
  19. 19.↵
    1. Haward B,
    2. Tatar O,
    3. Zhu P,
    4. Griffin-Mathieu G,
    5. McBride E,
    6. Waller J, et al.
    Are Canadian women prepared for the transition to primary HPV testing in cervical screening? A national survey of knowledge, attitudes, and beliefs. Curr Oncol 2023;30(7):7055-72.
    OpenUrl
  20. 20.↵
    1. Morgan K,
    2. Azzani M,
    3. Khaing SL,
    4. Wong YL,
    5. Su TT.
    Acceptability of women self-sampling versus clinician-collected samples for HPV DNA testing: a systematic review. J Low Genit Tract Dis 2019;23(3):193-9.
    OpenUrl
  21. 21.↵
    1. Schaafsma M,
    2. van den Helder R,
    3. Bleeker MCG,
    4. Rosier-van Dunné F,
    5. van der Avoort IAM,
    6. Steenbergen RDM, et al.
    Experiences and preferences towards collecting a urine and cervicovaginal self-sample among women attending a colposcopy clinic. Prev Med Rep 2022;26:101749.
    OpenUrl
  22. 22.↵
    1. Cadman L,
    2. Ashdown-Barr L,
    3. Waller J,
    4. Szarewski A.
    Attitudes towards cytology and human papillomavirus self-sample collection for cervical screening among Hindu women in London, UK: a mixed methods study. J Fam Plann Reprod Health Care 2015;41(1):38-47. Epub 2014 Feb 12.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Shin HY,
    2. Lee B,
    3. Hwang SH,
    4. Lee DO,
    5. Sung NY,
    6. Park JY, et al.
    Evaluation of satisfaction with three different cervical cancer screening modalities: clinician-collected Pap test vs. HPV test by self-sampling vs. HPV test by urine sampling. J Gynecol Oncol 2019;30(5):e76.
    OpenUrlPubMed
  24. 24.↵
    1. Bober P,
    2. Firment P,
    3. Sabo J.
    Diagnostic test accuracy of first-void urine human papillomaviruses for presence cervical HPV in women: systematic review and meta-analysis. Int J Environ Res Public Health 2021;18(24):13314.
    OpenUrl
  25. 25.↵
    1. Mao C,
    2. Kulasingam SL,
    3. Whitham HK,
    4. Hawes SE,
    5. Lin J,
    6. Kiviat NB.
    Clinician and patient acceptability of self-collected human papillomavirus testing for cervical cancer screening. J Womens Health (Larchmt) 2017;26(6):609-15. Epub 2017 Mar 23.
    OpenUrl
  26. 26.↵
    1. Smith LW,
    2. Racey CS,
    3. Gondara L,
    4. Krajden M,
    5. Lee M,
    6. Martin RE, et al.
    Women’s acceptability of and experience with primary human papillomavirus testing for cervix screening: HPV FOCAL trial cross-sectional online survey results. BMJ Open 2021;11(10):e052084.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Naimer MS,
    2. Kwong JC,
    3. Bhatia D,
    4. Moineddin R,
    5. Whelan M,
    6. Campitelli MA, et al.
    The effect of changes in cervical cancer screening guidelines on chlamydia testing. Ann Fam Med 2017;15(4):329-34.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Tatar O,
    2. Wade K,
    3. McBride E,
    4. Thompson E,
    5. Head KJ,
    6. Perez S, et al.
    Are health care professionals prepared to implement human papillomavirus testing? A review of psychosocial determinants of human papillomavirus test acceptability in primary cervical cancer screening. J Womens Health (Larchmt) 2020;29(3):390-405. Epub 2019 Sep 3.
    OpenUrl
  29. 29.↵
    1. Arbyn M,
    2. Smith SB,
    3. Temin S,
    4. Sultana F,
    5. Castle P; Collaboration on Self-Sampling and HPV Testing
    . Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ 2018;363:k4823.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Petignat P,
    2. Faltin DL,
    3. Bruchim I,
    4. Tramèr MR,
    5. Franco EL,
    6. Coutlée F.
    Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 2007;105(2):530-5. Epub 2007 Feb 28.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Bosgraaf RP,
    2. Ketelaars PJW,
    3. Verhoef VMJ,
    4. Massuger LFAG,
    5. Meijer CJLM,
    6. Melchers WJG, et al.
    Reasons for non-attendance to cervical screening and preferences for HPV self-sampling in Dutch women. Prev Med 2014;64:108-13. Epub 2014 Apr 13.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 70 (7-8)
Canadian Family Physician
Vol. 70, Issue 7-8
July/August 2024
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Are we ready for human papillomavirus testing?
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Are we ready for human papillomavirus testing?
Praniya Elangainesan, Michelle S. Naimer, Sahana Kukan, Amanda Selk
Canadian Family Physician Jul 2024, 70 (7-8) 479-490; DOI: 10.46747/cfp.700708479

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Are we ready for human papillomavirus testing?
Praniya Elangainesan, Michelle S. Naimer, Sahana Kukan, Amanda Selk
Canadian Family Physician Jul 2024, 70 (7-8) 479-490; DOI: 10.46747/cfp.700708479
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • Access to sexual health care
  • PubMed
  • Google Scholar

Cited By...

  • Uptake and feasibility of HPV self-sampling among patients of a Canadian family medicine clinic
  • Access to sexual health care: How family physicians can open the door
  • Google Scholar

More in this TOC Section

  • Experiences and preferences of people without access to primary care
  • Uptake and feasibility of HPV self-sampling among patients of a Canadian family medicine clinic
  • Author ordering and citation-based measures of scholarly impact
Show more Research

Similar Articles

Subjects

  • Collection française
    • Résumés de recherche

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire